Allesandro Riva, MD

Articles by Allesandro Riva, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,Michael Smylie, MD,John R. Mackey, MD,Dick Au, MD,Evelyn Sansregret, MD,Daniel Noel, MD,Alexander H. Paterson, MD,Taher Al-tweigeri, MD,Fernad Delorme, MD,Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,B. Thuerlimann, MD,W. R. Bezwoda, MD,D. Melnychuk, MD,L. Deschênes, MD,J. Douma, MD,T. A. Vandenberg, MD,B. Rapoport, MD,R. Rosso, MD,V. Trillet-lenoir, MD,J. Drbal, MD,Matti S. Aapro, MD,M. Alaki, MD,M. Murawsky, MD,Allesandro Riva, MD

August 1st 1997

This nonblinded, multicenter, randomized phase III study compares the median time to progression (primary endpoint), response rate, and quality of life, safety, and survival of

Latest Updated Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer
August 1st 1997
Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer
August 1st 1997

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)